We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Motif Bio Plc | LSE:MTFB | London | Ordinary Share | GB00BVVT4H71 | ORD 0.01P |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00% | 0.50 | 0.40 | 0.55 | 0.00 | 01:00:00 |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| 0 | 0 | N/A | 0 |
From Apr 2019 to Apr 2024
TIDMMTFB
RNS Number : 2820W
Motif Bio PLC
08 February 2017
8 February 2017
This announcement contains inside information
Motif Bio plc
("Motif Bio" or the "Company")
Director and PDMR dealing - grant of options
Motif Bio plc (AIM: MTFB), the clinical stage biopharmaceutical company specialising in developing novel antibiotics, announces that the Company has granted options to purchase ordinary shares of 1 pence each of Motif Bio ("Ordinary Shares") to a Director and certain PDMRs of the Company as follows:
Hot Features
Premium
Number of options Exercise Total number
granted price of options
held following
the grant
---------------- ------------------ --------- ----------------
Director
---------------- ------------------ --------- ----------------
Graham Lumsden 1,700,000 26p 5,148,800
---------------- ------------------ --------- ----------------
PDMR
---------------- ------------------ --------- ----------------
David Huang 1,000,000 26p 1,818,500
---------------- ------------------ --------- ----------------
Rajesh Shukla 300,000 26p 600,000
---------------- ------------------ --------- ----------------
Robert Dickey
IV 600,000 26p 2,100,000
---------------- ------------------ --------- ----------------
For Graham Lumsden, 1,000,000 options vest monthly over 4 years from the date of grant, and the remaining 700,000 options vest monthly over 4 years from the date of data read out on REVIVE-1 trial which is expected in the 2(nd) quarter of 2017. For Robert Dickey IV, 150,000 options vest on the anniversary date of the commencement of his employment, and the remaining 450,000 options vest monthly over the following 3 years. David Huang's and Rajesh Shukla's options vest monthly over 4 years from grant.
The options have an exercise price of 26 pence per Ordinary Share, being the closing price of the Ordinary Shares on 7 February 2017, the date of grant of the options.
The notification below, made in accordance with the requirements of the EU Market Abuse Regulation, provides further detail.
1 Details of the person discharging managerial
responsibilities/person closely associated
------- --------------------------------------------------------------
a) Name Graham Lumsden
------- ------------------------------- -----------------------------
2 Reason for the notification
------- --------------------------------------------------------------
Chief Executive Officer,
a) Position/status Director
------- ------------------------------- -----------------------------
b) Initial notification/Amendment Initial Notification
------- ------------------------------- -----------------------------
3 Details of the issuer, emission allowance market
participant, auction platform, auctioneer or
auction monitor
------- --------------------------------------------------------------
a) Name Motif Bio plc
------- ------------------------------- -----------------------------
b) LEI 54930080DN00QTIUUU84
------- ------------------------------- -----------------------------
4 Details of the transaction(s): section to be
repeated for (i) each type of instrument; (ii)
each type of transaction; (iii) each date;
and (iv) each place where transactions have
been conducted
------- --------------------------------------------------------------
a) Description of the Ordinary Shares
financial instrument,
type of instrument ISIN GB00BVVT4H71
Identification code
------- ------------------------------- -----------------------------
b) Nature of the transaction Grant of options to purchase
1,700,000 Ordinary Shares
------- ------------------------------- -----------------------------
c) Price(s) and volume(s) Price(s) Volume(s)
---------- ----------
N/A 1,700,000
---------- ----------
------- ------------------------------- -----------------------------
d) Aggregated information Price(s) Volume(s)
---------- ----------
N/A 1,700,000
---------- ----------
------- ------------------------------- -----------------------------
e) Date of the transaction 7 February 2017
------- ------------------------------- -----------------------------
f) Place of the transaction N/A
------- ------------------------------- -----------------------------
1 Details of the person discharging managerial
responsibilities/person closely associated
------- ----------------------------------------------------------------
a) Name David Huang
------- --------------------------------- -----------------------------
2 Reason for the notification
------- ----------------------------------------------------------------
Chief Medical Officer, PDMR
a) Position/status
------- --------------------------------- -----------------------------
b) Initial notification/Amendment Initial Notification
------- --------------------------------- -----------------------------
3 Details of the issuer, emission allowance market
participant, auction platform, auctioneer or
auction monitor
------- ----------------------------------------------------------------
a) Name Motif Bio plc
------- --------------------------------- -----------------------------
b) LEI 54930080DN00QTIUUU84
------- --------------------------------- -----------------------------
4 Details of the transaction(s): section to be
repeated for (i) each type of instrument; (ii)
each type of transaction; (iii) each date;
and (iv) each place where transactions have
been conducted
------- ----------------------------------------------------------------
a) Description of the Ordinary Shares
financial instrument,
type of instrument ISIN GB00BVVT4H71
Identification code
------- --------------------------------- -----------------------------
b) Nature of the transaction Grant of options to purchase
1,000,000 Ordinary Shares
------- --------------------------------- -----------------------------
c) Price(s) and volume(s) Price(s) Volume(s)
---------- ----------
N/A 1,000,000
---------- ----------
------- --------------------------------- -----------------------------
d) Aggregated information Price(s) Volume(s)
---------- ----------
N/A 1,000,000
---------- ----------
------- --------------------------------- -----------------------------
e) Date of the transaction 7 February 2017
------- --------------------------------- -----------------------------
f) Place of the transaction N/A
------- --------------------------------- -----------------------------
1 Details of the person discharging managerial
responsibilities/person closely associated
------- ----------------------------------------------------------------
a) Name Rajesh Shukla
------- --------------------------------- -----------------------------
2 Reason for the notification
------- ----------------------------------------------------------------
Vice President Clinical
a) Position/status Operations, PDMR
------- --------------------------------- -----------------------------
b) Initial notification/Amendment Initial Notification
------- --------------------------------- -----------------------------
3 Details of the issuer, emission allowance market
participant, auction platform, auctioneer or
auction monitor
------- ----------------------------------------------------------------
a) Name Motif Bio plc
------- --------------------------------- -----------------------------
b) LEI 54930080DN00QTIUUU84
------- --------------------------------- -----------------------------
4 Details of the transaction(s): section to be
repeated for (i) each type of instrument; (ii)
each type of transaction; (iii) each date;
and (iv) each place where transactions have
been conducted
------- ----------------------------------------------------------------
a) Description of the Ordinary Shares
financial instrument,
type of instrument ISIN GB00BVVT4H71
Identification code
------- --------------------------------- -----------------------------
b) Nature of the transaction Grant of options to purchase
300,000 Ordinary Shares
------- --------------------------------- -----------------------------
c) Price(s) and volume(s) Price(s) Volume(s)
---------- ----------
N/A 300,000
---------- ----------
------- --------------------------------- -----------------------------
d) Aggregated information Price(s) Volume(s)
---------- ----------
N/A 300,000
---------- ----------
------- --------------------------------- -----------------------------
e) Date of the transaction 7 February 2017
------- --------------------------------- -----------------------------
f) Place of the transaction N/A
------- --------------------------------- -----------------------------
1 Details of the person discharging managerial
responsibilities/person closely associated
------- ----------------------------------------------------------------
a) Name Robert Dickey IV
------- ------------------------------- -------------------------------
2 Reason for the notification
------- ----------------------------------------------------------------
Chief Financial Officer,
a) Position/status PDMR
------- ------------------------------- -------------------------------
b) Initial notification/Amendment Initial Notification
------- ------------------------------- -------------------------------
3 Details of the issuer, emission allowance market
participant, auction platform, auctioneer or
auction monitor
------- ----------------------------------------------------------------
a) Name Motif Bio plc
------- ------------------------------- -------------------------------
b) LEI 54930080DN00QTIUUU84
------- ------------------------------- -------------------------------
4 Details of the transaction(s): section to be
repeated for (i) each type of instrument; (ii)
each type of transaction; (iii) each date;
and (iv) each place where transactions have
been conducted
------- ----------------------------------------------------------------
a) Description of the Ordinary Shares
financial instrument,
type of instrument ISIN GB00BVVT4H71
Identification code
------- ------------------------------- -------------------------------
b) Nature of the transaction Grant of options to purchase
600,000 Ordinary Shares
------- ------------------------------- -------------------------------
c) Price(s) and volume(s) Price(s) Volume(s)
---------- ----------
N/A 600,000
---------- ----------
------- ------------------------------- -------------------------------
d) Aggregated information Price(s) Volume(s)
---------- ----------
N/A 600,000
---------- ----------
------- ------------------------------- -------------------------------
e) Date of the transaction 7 February 2017
------- ------------------------------- -------------------------------
f) Place of the transaction N/A
------- ------------------------------- -------------------------------
For further information please contact:
Motif Bio plc info@motifbio.com Graham Lumsden (Chief Executive Officer) Zeus Capital Limited (NOMAD & BROKER) Phil Walker/Giles Balleny Dominic Wilson +44 (0)20 3829 5000 Northland Capital Partners Limited (BROKER) Patrick Claridge/David Hignell John Howes/Rob Rees (Broking) +44 (0)20 3861 6600 Walbrook PR Ltd. (FINANCIAL +44 (0)20 7933 8780 or motifbio@walbrookpr.com PR & IR) Mob: +44 (0)7980 541 893 Paul McManus Mob: +44 (0)7900 608 002 Mike Wort MC Services AG (EUROPEAN IR) Raimund Gabriel +49 (0)89 210 2280
Notes to Editors:
Motif Bio is a clinical-stage biopharmaceutical company, engaged in the research and development of novel antibiotics designed to be effective against serious and life-threatening infections in hospitalised patients caused by multi-drug resistant bacteria. Our lead product candidate, iclaprim, is being developed for the treatment of acute bacterial skin and skin structure infections (ABSSSI) and hospital acquired bacterial pneumonia (HABP), including ventilator associated bacterial pneumonia (VABP), which is often caused by MRSA (methicillin resistant Staphylococcus aureus). We are currently enrolling and dosing patients in two global Phase 3 clinical trials (Revive 1 and Revive 2) with an intravenous formulation of iclaprim, for the treatment of ABSSSI. Data readout for REVIVE-1 is expected in the second quarter of 2017 and REVIVE-2 is on track for data readout in the second half of 2017.
This information is provided by RNS
The company news service from the London Stock Exchange
END
DSHEAEAXEFFXEAF
(END) Dow Jones Newswires
February 08, 2017 02:00 ET (07:00 GMT)
1 Year Motif Bio Chart |
1 Month Motif Bio Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
